Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 15/20 | 0.81 |
| ▸ | SCN3A | Q9NY46 | 8/20 | 0.81 |
| ▸ | SCN1A | P35498 | 1/20 | 0.81 |
| ▸ | SCN4A | P35499 | 1/20 | 0.81 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.81 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.81 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.81 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.81 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.81 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.81 |
| ▸ | MAOB | P27338 | 3/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.79 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.79 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.51 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.51 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10080247 | 1.00 | KCNH2 (0.81) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL2836373 | 0.94 | KCNH2 (0.72) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL2830886 | 0.94 | KCNH2 (0.72) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| Vixotrigine SCHEMBL2831660 | 0.89 | KCNH2 (1.00) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| Vixotrigine SCHEMBL862457 | 0.89 | KCNH2 (1.00) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL862168 | 0.89 | KCNH2 (0.79) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| Vixotrigine SCHEMBL311438 | 0.89 | KCNH2 (1.00) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| Vixotrigine SCHEMBL840590 | 0.89 | KCNH2 (1.00) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL862451 | 0.89 | KCNH2 (0.79) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL13320297 | 0.89 | KCNH2 (0.79) | KCNH2SCN3ASCN1ASCN4ASCN7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177426-A1 | PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES | BIOGEN MA INC. | 2022-06-09 | — | — | US | disclosed |
| EP-3953329-A1 | PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES | Biogen MA Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| CN-114026066-A | Process for preparing alpha-carboxamide pyrrolidine derivatives | 生物基因麻省公司 | 2022-02-08 | — | — | CN | disclosed |
| US-20210154170-A1 | METHODS OF TREATING NEUROPATHIC PAIN | BIOGEN MA INC. | 2021-05-27 | — | — | US | disclosed |
| WO-2020210485-A1 | PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES | BIOGEN MA INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| EP-2461807-A1 | CO-THERAPY FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS | Convergence Pharmaceuticals Limited (GB) | 2012-06-13 | — | — | EP | disclosed |
| EP-1934177-B1 | PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GLAXO GROUP LTD (GB) | 2012-05-02 | — | — | EP | disclosed |
| US-20100324022-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | US | disclosed |
| US-7855218-B2 | (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide; depression or a mood disorder ; modulation of use-dependent voltage-gated sodium channels | Convergence Pharmaceuticals Limited (GB) | 2010-12-21 | — | — | US | disclosed |
| US-7803833-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| US-20090318530-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| EP-2129655-A1 | PROLINAMIDE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED SODIUM CHANNELS | Glaxo Group Limited (GB) | 2009-12-09 | — | — | EP | disclosed |
| US-20080306122-A1 | Novel Compounds | Convergence Pharmaceuticals Limited (GB) | 2008-12-11 | — | — | US | disclosed |
| US-20080293753-A1 | Novel Compounds | Convergence Pharmaceuticals Limited (GB) | 2008-11-27 | — | — | US | disclosed |
| US-20080280969-A1 | Novel Compounds | GLAXO GROUP LIMITED | 2008-11-13 | — | — | US | disclosed |
| WO-2008122546-A1 | PROLINAMIDE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED SODIUM CHANNELS | GLAXO GROUP LIMITED (GB) | 2008-10-16 | — | — | WO | disclosed |
| EP-1934176-A1 | QUATERNARY ALPHA-AMINOCARBOXAMIDE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED SODIUM CHANNELS | GLAXO GROUP LIMITED (GB) | 2008-06-25 | — | — | EP | disclosed |
| EP-1934177-A1 | PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GLAXO GROUP LIMITED (GB) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007042239-A1 | PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GLAXO GROUP LIMITED (GB) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007042240-A1 | QUATERNARY ALPHA-AMINOCARBOXAMIDE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED SODIUM CHANNELS | GLAXO GROUP LIMITED (GB) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318530-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS | HCRTR1, TACR2, CNR1 | KCNH2 7/4885SCN3A 45/4885SCN1A 16/4885 |
| US-20100324022-A1 | NOVEL COMPOUNDS | CYP46A1, NPC1, CYP11B1 | KCNH2 3260/4885SCN3A 2696/4885SCN1A 1086/4885 |
| US-20080306122-A1 | Novel Compounds | CYP11B1, CYP11B2, CYP46A1 | KCNH2 3313/4885SCN3A 2352/4885SCN1A 691/4885 |
| US-20220177426-A1 | PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES | CPS1, PCCA, ALDH18A1 | KCNH2 774/4885SCN3A 2474/4885SCN1A 1640/4885 |
| US-20210154170-A1 | METHODS OF TREATING NEUROPATHIC PAIN | OPRL1, PMP22, PRPH | KCNH2 811/4885SCN3A 13/4885SCN1A 93/4885 |
| US-20080280969-A1 | Novel Compounds | CYP11B2, CYP46A1, SLC10A1 | KCNH2 1998/4885SCN3A 2634/4885SCN1A 1089/4885 |
| US-20080293753-A1 | Novel Compounds | CACNA1E, CACNA1A, SCN1B | KCNH2 15/4885SCN3A 11/4885SCN1A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.